vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2011-1-17-26vtio-354Research ArticleКлиническая трансплантологияClinical TransplantologyИЗУЧЕНИЕ ВОЗМОЖНОСТЕЙ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ГЕПАТИТА С ТРАНСПЛАНТАТА ПЕЧЕНИPOSSIBILITIES OF HEPATITIS C ANTIVIRAL TREATMENT IN LIVER TRANSPLANT RECIPIENTSСюткинВ. Е.SyutkinV. E.АндрейцеваО. И.AndreytzevaO. I.ЧжаоА. В.ChzhaoA. V.Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского, МоскваРоссияN.V. Sklifosovsky institute recearch of Emergency Medicine, MoscowRussian FederationНаучно-исследовательский институт скорой помощи им. Н.В. Склифосовского, Москва Кафедра трансплантологии и искусственных органов МГМСУРоссияChair of transplantology of the 3d Moscow Medical UniversityRussian Federation201109062014131ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XIII No 1–20111726Copyright © Сюткин В.Е., Андрейцева О.И., Чжао А.В., 20112011Сюткин В.Е., Андрейцева О.И., Чжао А.В.Syutkin V.E., Andreytzeva O.I., Chzhao A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/354

Обобщен собственный опыт противовирусной терапии возвратной инфекции HCV после транспланта- ции печени. С 2002 по 2010 гг. 19 пациентов получили 22 курса лечения пегилированными интерфе- ронами и рибавирином. Стойкий вирусологический ответ составил 25% при анализе в зависимости от назначенного лечения и 40% при анализе per protocol. Применение факторов роста позволило уменьшить частоту снижения доз противовирусных препаратов и перерывов в терапии. Авторы обращают внимание на медленную раннюю вирусную кинетику в изученной группе больных, что обосновывает увеличение продолжительности противовирусной терапии более 48 недель. 

The results of 21 courses of antiviral therapy (AT) in 18 pts with HCV infection after cadaveric liver transplan- tation have been analyzed. (One recipient received AT twice due to noncompliance and two patients re-started AT PEG-IFN monotherapy). AT included PEG–IFN alpha-2a (180 mcg/w) in 18 cases or PEG-IFN alpha-2b (1,5 mcg/kg/w) in 3 cases combined with RBV (9,9 (3,3) mg/kg/day). Since 2008 epoetin-alfa (30,000 U/w) and filgrastim (300 mcg/w) were added to correct cytopenias for all treatment duration. Sustained virologic response was achieved in 25% cases (ITT) or in 40% cases (completed 80/80/80 rule per protocol). Rapid virologic res- ponse occurred only in 2 patients with non-1 genotype HCV with respectively low viral load, and complete early virologic response (EVR) – in 10 (56%) of 18 patients. Complete EVR occurred in all non-1 genotype pts, but only in 5/13 pts with HCV genotype 1 (p = 0,036). Four pts achieved negative serum HCV RNA post 12 week of AT. The early viral dynamic is slower in AT of recurrent HCV infection in liver transplant recipients than in non-transplanted patients. Growth factors can safely and effectively be used in complex treatment of hepatitis C after liver transplantation. 

трансплантация печенипротивовирусная терапияпегилированные интерферонырибавирингепатит Сliver transplantationantiviral therapyPEG-IFNribavirinhepatitis CReferencesСюткин В.Е. Стратегия лечения больных хрониче- ским гепатитом C на современном этапе // Клиниче- ская фармакология и терапия. 2008. Т. 17 (2). С. 16–19.Сюткин В.Е. Стратегия лечения больных хрониче- ским гепатитом C на современном этапе // Клиниче- ская фармакология и терапия. 2008. Т. 17 (2). С. 16–19.Сюткин В.Е. Новые возможности повышения эф- фективности противовирусной терапии больных хроническим гепатитом С // Инфекционные болезни. 2009. Т. 7. No 2. С. 55–59.Сюткин В.Е. Новые возможности повышения эф- фективности противовирусной терапии больных хроническим гепатитом С // Инфекционные болезни. 2009. Т. 7. No 2. С. 55–59.Adeyemi O.M. Hepatitis C in HIV-positive patients— treatment and liver disease outcomes // J Clin Gastroen- terol. 2007. Vol. 41. P. 75–87Adeyemi O.M. Hepatitis C in HIV-positive patients— treatment and liver disease outcomes // J Clin Gastroen- terol. 2007. Vol. 41. P. 75–87Alter H.J., Seeff L.B. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000. Vol. 20. P. 17–35.Alter H.J., Seeff L.B. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000. Vol. 20. P. 17–35.Bahra M., Neumann U.P., Jacob D. et al. Fibrosis pro- gression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy) // Transplantation. 2007. Vol. 83. P. 351–353.Bahra M., Neumann U.P., Jacob D. et al. Fibrosis pro- gression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy) // Transplantation. 2007. Vol. 83. P. 351–353.Berenguer M. Systematic review of the treatment of es- tablished recurrent hepatitis C with pegylated interferon in combination with ribavirin // J Hepatol. 2008. Vol. 49. P. 274–287.Berenguer M. Systematic review of the treatment of es- tablished recurrent hepatitis C with pegylated interferon in combination with ribavirin // J Hepatol. 2008. Vol. 49. P. 274–287.Berenguer M., Palau A., Fernandez A. et al. Efficacy, pre- dictors of response, and potential risks associated with an- tiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006. Vol. 12. P. 1067–1076.Berenguer M., Palau A., Fernandez A. et al. Efficacy, pre- dictors of response, and potential risks associated with an- tiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2006. Vol. 12. P. 1067–1076.Berenguer M., Prieto M., Rayon J.M. et al. Natural his- tory of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000. 32. P. 852–858.Berenguer M., Prieto M., Rayon J.M. et al. Natural his- tory of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000. 32. P. 852–858.Bizollon T., Pradat P., Mabrut J.Y. et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with re- current chronic hepatitis C // Am. J. Transplant. 2005. Vol. 5. P. 1909–1913.Bizollon T., Pradat P., Mabrut J.Y. et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with re- current chronic hepatitis C // Am. J. Transplant. 2005. Vol. 5. P. 1909–1913.Castells L., Vargas V., Allende H. et al. Combined treat- ment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation // J. Hepatol. 2005. Vol. 43. P. 53–59.Castells L., Vargas V., Allende H. et al. Combined treat- ment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation // J. Hepatol. 2005. Vol. 43. P. 53–59.Chalasani N., Manzarbeitia C., Ferenci P. et al. Pegin- terferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trial (published erratum ap- pears in Hepatology 2005. Vol. 42. P. 506). Hepatology. 2005. Vol. 41. P. 289–298.Chalasani N., Manzarbeitia C., Ferenci P. et al. Pegin- terferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trial (published erratum ap- pears in Hepatology 2005. Vol. 42. P. 506). Hepatology. 2005. Vol. 41. P. 289–298.Donato M., Agnelli F., Rigamonti C.et al. Might Rapid Virological Response Be Used as a Stopping Rule in Liver Transplant Recipients Treated with Pegylated In- terferon Plus Ribavirin? Liver transplantation. 2008. Vol. 14. P. 1383–1384Donato M., Agnelli F., Rigamonti C.et al. Might Rapid Virological Response Be Used as a Stopping Rule in Liver Transplant Recipients Treated with Pegylated In- terferon Plus Ribavirin? Liver transplantation. 2008. Vol. 14. P. 1383–1384Dumortier J., Scoazec J.Y., Chevallier P. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinati- on // J. Hepatol 2004. Vol. 40. P. 669–674.Dumortier J., Scoazec J.Y., Chevallier P. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinati- on // J. Hepatol 2004. Vol. 40. P. 669–674.Fried M., Shiffman M., Reddy K. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infec- tion. N. Engl. J. Med. 2002. Vol. 347. P. 975–982.Fried M., Shiffman M., Reddy K. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infec- tion. N. Engl. J. Med. 2002. Vol. 347. P. 975–982.Gane E.J., Naoumov N.V., Qian K.P. et al. A longitudi- nal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996. Vol. 110. P. 167–177.Gane E.J., Naoumov N.V., Qian K.P. et al. A longitudi- nal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996. Vol. 110. P. 167–177.Gish R.G., Afdhal N.H., Dieterich D.T., Reddy KR. Man- agement of hepatitis C virus in special populations: pa- tient and treatment considerations. Clin Gastroenterol Hepatol. 2005. Vol. 3. P. 311–318.Gish R.G., Afdhal N.H., Dieterich D.T., Reddy KR. Man- agement of hepatitis C virus in special populations: pa- tient and treatment considerations. Clin Gastroenterol Hepatol. 2005. Vol. 3. P. 311–318.Gurusamy K.S., Tsochatzis E., Xirouchakis E. et al. An- tiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010. Vol. 20 (1). CD006803. Review.Gurusamy K.S., Tsochatzis E., Xirouchakis E. et al. An- tiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010. Vol. 20 (1). CD006803. Review.HanounehI.A., Miller C., Aucejo F. et al. Recurrent hepa- titis C after liver transplantation: on treatment prediction of response to peginterferon/ribavirin therapy // Liver Transpl. 2008. Vol. 14. P. 53–58.HanounehI.A., Miller C., Aucejo F. et al. Recurrent hepa- titis C after liver transplantation: on treatment prediction of response to peginterferon/ribavirin therapy // Liver Transpl. 2008. Vol. 14. P. 53–58.Ikegami T., Taketomi A., Soejima Y. et al. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hep- atitis C // Transplant Proc. 2009. Vol. 41 (10). P. 4246– 4252.Ikegami T., Taketomi A., Soejima Y. et al. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hep- atitis C // Transplant Proc. 2009. Vol. 41 (10). P. 4246– 4252.Lilly L., Selzner N., Therapondos G. et al. Improved sur- vival in liver transplant recipients (LT) treated for recur- rent hepatitis C (HCV) is seen in both relapsers and in sustained responders. Paper presented at: 2008 American Transplant Congress; May 31–June 4, 2008. Toronto, Canada.Lilly L., Selzner N., Therapondos G. et al. Improved sur- vival in liver transplant recipients (LT) treated for recur- rent hepatitis C (HCV) is seen in both relapsers and in sustained responders. Paper presented at: 2008 American Transplant Congress; May 31–June 4, 2008. Toronto, Canada.Manns M., McHutchison J., Gordon S. et al. Peginterfe- ron alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001. Vol. 358. P. 958–965.Manns M., McHutchison J., Gordon S. et al. Peginterfe- ron alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001. Vol. 358. P. 958–965.Moeller M., Divine G., Brown K.A. Impact of length of therapy and predictive value models on SVR in HCV pa- tients post OLT. Hepatology. 2009. Vol. 50. 391A.Moeller M., Divine G., Brown K.A. Impact of length of therapy and predictive value models on SVR in HCV pa- tients post OLT. Hepatology. 2009. Vol. 50. 391A.Oton E., Barcena R., Moreno-Planas J.M. et al. Hepa- titis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ri- bavirin. Am. J. Transplant. 2006. Vol. 6. P. 2348–2355.Oton E., Barcena R., Moreno-Planas J.M. et al. Hepa- titis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ri- bavirin. Am. J. Transplant. 2006. Vol. 6. P. 2348–2355.Picciotto F.P.,Tritto G., Lanza A.G. et al. Sustained viro- logical response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation // J. Hepatol. 2007. Vol. 46. P. 459–465Picciotto F.P.,Tritto G., Lanza A.G. et al. Sustained viro- logical response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation // J. Hepatol. 2007. Vol. 46. P. 459–465Roche B. and Samuel D. Aspects of hepatitis C virus in- fection relating to liver transplantation. Eur. J. Gastroen- terol Hepatol. 2005. Vol. 18. P. 313–320.Roche B. and Samuel D. Aspects of hepatitis C virus in- fection relating to liver transplantation. Eur. J. Gastroen- terol Hepatol. 2005. Vol. 18. P. 313–320.Samuel D., Bizollon T., Feray C. et al. Interferon-a2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterol- ogy. 2003. Vol. 124. P. 642–650.Samuel D., Bizollon T., Feray C. et al. Interferon-a2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterol- ogy. 2003. Vol. 124. P. 642–650.Schmidt S.C., Bahra M., Bayraktar S. et al. Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon. Dig Dis. Sci. 2010. Vol. 55 (7). P. 2063–2069.Schmidt S.C., Bahra M., Bayraktar S. et al. Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon. Dig Dis. Sci. 2010. Vol. 55 (7). P. 2063–2069.Sheiner P.A., Boros P., Klion F.M. et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998. Vol. 28. P. 831–838.Sheiner P.A., Boros P., Klion F.M. et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology. 1998. Vol. 28. P. 831–838.Terrault N.A., Berenguer M. Treating hepatitis C infec- tion in liver transplant recipients. Liver Transpl. 2006. Vol. /12. P. 1192–1204.Terrault N.A., Berenguer M. Treating hepatitis C infec- tion in liver transplant recipients. Liver Transpl. 2006. Vol. /12. P. 1192–1204.Torriani F.J., Ribeiro R.M., Gilbert T.L. et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)Torriani F.J., Ribeiro R.M., Gilbert T.L. et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)dynamics during HCV treatment in HCV/HIV coinfec-dynamics during HCV treatment in HCV/HIV coinfec-tion // J. Infect. Dis. 2003. Vol. 188. P. 1498–1507.tion // J. Infect. Dis. 2003. Vol. 188. P. 1498–1507.Ueda Y., Takada Y., Haga H. et al. Limited benefit of bio- chemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver trans-Ueda Y., Takada Y., Haga H. et al. Limited benefit of bio- chemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver trans-plantation. Transplantation. 2008. Vol. 85. P. 855–862.plantation. Transplantation. 2008. Vol. 85. P. 855–862.Veldt B.J., Poterucha J.J., Watt K.D.S. et al. Impact of pegylated interferon and ribavirin treatment on graft sur- vival in liver transplant patients with recurrent hepatitis C infection // Am. J. Transpl. 2008. Vol. 8. P. 2426–2433.Veldt B.J., Poterucha J.J., Watt K.D.S. et al. Impact of pegylated interferon and ribavirin treatment on graft sur- vival in liver transplant patients with recurrent hepatitis C infection // Am. J. Transpl. 2008. Vol. 8. P. 2426–2433.Walter T., Scoazec J.Y., Guillaud O. et al. Long-term anti- viral therapy for recurrent hepatitis C after liver transplan- tation in nonresponders: biochemical, virological, and his-Walter T., Scoazec J.Y., Guillaud O. et al. Long-term anti- viral therapy for recurrent hepatitis C after liver transplan- tation in nonresponders: biochemical, virological, and his-tological impact. Liver Transpl. 2009. Vol. 15. P. 54–63.tological impact. Liver Transpl. 2009. Vol. 15. P. 54–63.Wang C.S., Ko H.H., Yoshida E.M. et al. Interferon- based combination anti-viral therapy for hepatitis C vi- rus after liver transplantation: a review and quantitative analysis // Am. J. Transplant. 2006. Vol. 6. P. 1586–1599.Wang C.S., Ko H.H., Yoshida E.M. et al. Interferon- based combination anti-viral therapy for hepatitis C vi- rus after liver transplantation: a review and quantitative analysis // Am. J. Transplant. 2006. Vol. 6. P. 1586–1599.Xirouchakis E., Triantos C., Manousou P. et al. Pegyla- ted-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies //Xirouchakis E., Triantos C., Manousou P. et al. Pegyla- ted-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies //Journal of Viral Hepatitis. 2008. Vol. 15. P. 699–709.Journal of Viral Hepatitis. 2008. Vol. 15. P. 699–709.Zimmermann T., Bocher W.O., Biesterfeld S. et al. Ef- ficacy of an escalating dose regimen of pegylated inter- feron alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007.Zimmermann T., Bocher W.O., Biesterfeld S. et al. Ef- ficacy of an escalating dose regimen of pegylated inter- feron alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int. 2007.Vol. 20. P. 583–590.Vol. 20. P. 583–590.

The authors declare that there are no conflicts of interest present.